Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomatitis 2 Mucositis 2 Mouth Neoplasms 2 Head and Neck Neoplasms 2 Neuroendocrine Tumors 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Small Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 209 Fluorouracil 199 Irinotecan 192 Oxaliplatin 190 Leucovorin 179 Capecitabine 133 Cetuximab 129 Panitumumab 62 Folfox protocol 45 regorafenib 39 Radiotherapy 37 IFL protocol 35 pembrolizumab 34 HMPL-013 31 trifluridine tipiracil drug combination 28 Nivolumab 27 Neoadjuvant Therapy 24 Drug Therapy 22 tislelizumab 16 Celecoxib 16 aflibercept 15 XELOX 15 Chemotherapy, Adjuvant 15 Trifluridine 14 sintilimab 13 durvalumab 13 atezolizumab 13 Trastuzumab 13 Gemcitabine 13 Floxuridine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed

62 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡